Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the
orchestration of metabolic pathways in regulating ferroptosis will provide new insights into …

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease defined by the
absence of estrogen receptor (ER) and progesterone receptor (PR) expression, and human …

Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer
(TNBC); however, they benefited only a subset of patients, underscoring the need to co …